District of Columbia;
US Court of Appeals, Federal Circuit;
US Patent & Trademark Office;
USDC, District of Columbia;
USDC, District of Maryland
1050 Connecticut Ave., NW, Suite 500, Washington, DC 20036
Jeremy has represented numerous parties in patent litigation spanning a variety of fields, from automotive to biotechnology to medical devices to optics. He has extensive experience representing clients in life sciences patent litigation, especially in cases brought under the Hatch Waxman Act.
- Earned a complete victory for Amneal Pharmaceuticals over Noven Pharmaceuticals in connection with Amneal’s ANDA for a therapeutic equivalent of the Minivelle® estrogen patch; at trial, persuaded Judge Stark of the District of Delaware to invalidate all asserted claims of all three Noven patents for failure to meet both the written description and enablement requirements of Section 112 of the Patent Act.
- Persuaded the Federal Circuit entire panel, including Judge Newman, to affirm the decision of the PTAB that all claims of six patents were invalid as obvious; this victory over Jazz Pharmaceuticals helped pave the way for client Amneal Pharmaceuticals in connection with its bid to market a therapeutic equivalent of Xyrem® for the treatment of narcolepsy.
- Persuaded the Federal Circuit to vacate a trial decision rendered against Actavis after being brought on for the appeal, with the Federal Circuit instructing the district court to enter judgment of non-infringement in favor of Actavis.
- Secured complete victory for Allergan in first-to-file litigation over Beyaz® and Safyral® (Merck and Bayer), persuading a unanimous Federal Circuit panel to reverse and invalidate the patents under the on-sale bar.
- Scored a complete non-infringement victory for Watson before Judge Andrews in the United States District Court for the District of Delaware, obtaining a rare, expedited schedule and delivering a trial presentation so compelling that Judge Andrews announced his decision from the bench at the close of evidence, before any post-trial briefing.
- Super Lawyers® Rising Stars, Intellectual Property Litigation, 2014-2018
- JD, University of Maryland School of Law, With Honors (Moot Court), 2005
- BS, University of Maryland (Biology), University and Departmental Honors, Phi Beta Kappa, 2000
- Co-presenter. “ANDA Litigation Overview” Webinar for Shanghai IP Protection Center, December 21, 2022. (> 23,000 attendees)
- Author. “7 Ways Patent Litigators Can Leverage Inventor Testimony,” Law360, January 11, 2022. (Named to Law360’s list of most-read guest expert articles of 2022.)
- Co-author. “Trial in ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators,” American Bar Association, Section of Intellectual Property Law, 2020.
- Co-presenter. “Patent Litigation and the Power of Correlative Microscopy,” Microscopy Society of America’s Microscopy and Microanalysis 2014 Meeting, Hartford, CT, August 2014.
- Author. “Patent Litigation and the Power of Correlative Microscopy,” Microscopy and Microanalysis, Vol. 20, Supplement 3, 2014.
- Panelist. “Developments in Obviousness,” ACI Paragraph IV Disputes Conference, New York, NY, April 2014.
- Cruz, Adrian. “Procopio Cory Snags International M&A Attorney in Silicon Valley,” Law360, November 14, 2022.
- Mehta, Rani. “Novartis’s planned SCOTUS appeal may be a long shot, but the case raises interesting Section 112 and procedural questions, say counsel,” Managing IP, September 22, 2022.
- “Midsize Moves: Patent Litigators Join in D.C.,” The American Lawyer, February 24, 2022.
- Lidgett, Adam. “Health Hires,” Law360, February 18, 2022.
- Knaudt, Kamila. “Procopio expands east, hires two new life science partners for future D.C. office,” San Diego Daily Transcript, February 18, 2022.